Cambridge, UK:
o2h Ventures has been shortlisted as a finalist for the “Seed VC of the Year” at the UKBAA Angel Investment Awards 2025. This nomination highlights our dedication to fostering groundbreaking early-stage biotech innovations that are transforming the future of human health.
As a specialist biotech fund manager based in Cambridge’s thriving life sciences hub, o2h Ventures is at the forefront of identifying and accelerating pioneering ventures in pure-play therapeutics, biotech enablers, and AI/ML-driven biotechnology
With deep roots in the biotech ecosystem, o2h Ventures has built a unique flywheel model—combining capital investment with hands-on mentorship, team-building expertise, and commercialization support. The fund actively partners with university spinouts and visionary founders, guiding them from academic research to scalable, venture-backed businesses with real-world clinical and commercial impact.
Sunil Shah, CEO of o2h Ventures,
“This recognition is a significant milestone in our journey. It underscores the passion we bring to nurturing biotech innovation and accelerating the path from lab to full-grown biotech venture. We take immense pride in supporting founders who are pushing the boundaries of science, and this nomination reflects the collective effort of our portfolio companies, partners, and the broader Cambridge ecosystem.”
The UKBAA Angel Investment Awards celebrates the success and determination of the angel and early-stage investment community. The 2025 ceremony will take place on July 10th at The Brewery, London, bringing together investors, founders, and innovators to celebrate excellence in the sector.
Find out more about the Awards and see the other finalists here: awards.ukbaa.org.uk
